WHO Halts Hydroxychloroquine Trial Over Safety Concerns

2 min


59
10 shares, 59 points
WHO Halts Hydroxychloroquine Trial Over Safety Concerns

A pharmacy tech pours out pills of hydroxychloroquine May 20 at Rock Canyon Pharmacy in Provo, Utah, on May 20, 2020. After a study found COVID-19 patients using the drug were dying at higher rates, the World Health Organization announced it would suspend its clinical trial. George Frey/AFP via Getty Images hide caption

toggle caption

George Frey/AFP via Getty Images

A pharmacy tech pours out pills of hydroxychloroquine May 20 at Rock Canyon Pharmacy in Provo, Utah, on May 20, 2020. After a study found COVID-19 patients using the drug were dying at higher rates, the World Health Organization announced it would suspend its clinical trial.

George Frey/AFP via Getty Images

The World Health Organization says it is temporarily halting its clinical trials that use hydroxychloroquine to treat COVID-19 patients over published concerns that the drug may do more harm than good.

The move comes after the medical journal The Lancet reported on Friday that patients getting hydroxychloroquine were dying at higher rates than other coronavirus patients.

The WHO has 3,500 patients from 17 countries enrolled in what it calls the Solidarity Trial. This is an effort overseen by the WHO to find new treatments for COVID-19. The patients in the trial have been randomly assigned to be treated with hydroxychloroquine which is a common malaria drug, or 3 other experimental drugs for treating COVID-19 in various combinations. Only the hydroxychloroquine part of the trial is being put on hold.

“The review will consider data collected so far in the Solidarity Trial and in particular robust, randomized available data to adequately evaluate the potential benefits and harms from this drug [hydroxycholoroquine],” WHO Director General Tedros Adhanom Ghebreyesus said during an online press conference from Geneva on Monday.

The WHO’s chief scientist, Soumya Swaminathan, says the review was prompted by the article in The Lancet, which was not a randomized control trial but still large.

“While it was still a reporting of observational data,” Swaminathan says, distinguishing it from the gold-standard randomized controlled trial, “it came from multiple registries and quite a large number of patients, 96,000 patients.” She says the WHO hasn’t yet seen data that showed a problem with hydroxychloroquine in its own study but The Lancet article raised questions among many of the investigators involved in the WHO’s trial.

“The steering committee met over the weekend, in the light of this uncertainty,” Swaminathan says. “We decided we should be proactive, err on the side of caution and suspend enrollment temporarily into the hydroxychloroquine arm [of the Solidarity trial].”

President Trump has advocated for the use of hydroxychloroquine during the pandemic despite limited research into whether it is effective against the virus. The president has said he’s been taking hydroxychloroquine to protect against the virus. The trials being put on hold by the WHO are investigating its use as a treatment for patients who are hospitalized with COVID-19, not as a drug to prevent the disease.

The review panel will also check on seven other studies globally including the Recovery Trial in the United Kingdom that are using hydroxychloroquine for COVID-19 patients to see if they are seeing similar problems.

Swaminathan says they expect to decide whether to resume testing hydroxychloroquine in the Solidarity Trial in a week or two.


Like it? Share with your friends!

59
10 shares, 59 points

What's Your Reaction?

hate hate
16
hate
confused confused
8
confused
fail fail
2
fail
fun fun
20
fun
geeky geeky
18
geeky
love love
12
love
lol lol
14
lol
omg omg
8
omg
win win
2
win

Read exclusive latest news on entertainment, music, gaming and more topics with unprecedented coverage from around the UK and US.

0 Comments

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.